These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15273089)

  • 1. Prediction of mechanisms of action of antibacterial compounds by gene expression profiling.
    Hutter B; Schaab C; Albrecht S; Borgmann M; Brunner NA; Freiberg C; Ziegelbauer K; Rock CO; Ivanov I; Loferer H
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2838-44. PubMed ID: 15273089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enoyl-ACP reductase (FabI) of Haemophilus influenzae: steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene.
    Marcinkeviciene J; Jiang W; Kopcho LM; Locke G; Luo Y; Copeland RA
    Arch Biochem Biophys; 2001 Jun; 390(1):101-8. PubMed ID: 11368521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis.
    Hoang TT; Schweizer HP
    J Bacteriol; 1999 Sep; 181(17):5489-97. PubMed ID: 10464225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
    Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
    Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-of-Action Classification of Antibiotics by Global Transcriptome Profiling.
    O'Rourke A; Beyhan S; Choi Y; Morales P; Chan AP; Espinoza JL; Dupont CL; Meyer KJ; Spoering A; Lewis K; Nierman WC; Nelson KE
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A view of development of new antibacterial agents with novel targets].
    Watanabe Y; Minami S
    Nihon Rinsho; 2003 Mar; 61 Suppl 3():248-53. PubMed ID: 12717979
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovering the mechanism of action of novel antibacterial agents through transcriptional profiling of conditional mutants.
    Freiberg C; Fischer HP; Brunner NA
    Antimicrob Agents Chemother; 2005 Feb; 49(2):749-59. PubMed ID: 15673760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene.
    Heath RJ; Li J; Roland GE; Rock CO
    J Biol Chem; 2000 Feb; 275(7):4654-9. PubMed ID: 10671494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan.
    Ward WH; Holdgate GA; Rowsell S; McLean EG; Pauptit RA; Clayton E; Nichols WW; Colls JG; Minshull CA; Jude DA; Mistry A; Timms D; Camble R; Hales NJ; Britton CJ; Taylor IW
    Biochemistry; 1999 Sep; 38(38):12514-25. PubMed ID: 10493822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK).
    Marrakchi H; Dewolf WE; Quinn C; West J; Polizzi BJ; So CY; Holmes DJ; Reed SL; Heath RJ; Payne DJ; Rock CO; Wallis NG
    Biochem J; 2003 Mar; 370(Pt 3):1055-62. PubMed ID: 12487627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis.
    Betts JC; McLaren A; Lennon MG; Kelly FM; Lukey PT; Blakemore SJ; Duncan K
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2903-13. PubMed ID: 12936993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel enoyl-acyl carrier protein reductase of diazaborine-resistant Rhodobacter sphaeroides mutant.
    Lee IH; Kim EJ; Cho YH; Lee JK
    Biochem Biophys Res Commun; 2002 Dec; 299(4):621-7. PubMed ID: 12459184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase.
    Ling LL; Xian J; Ali S; Geng B; Fan J; Mills DM; Arvanites AC; Orgueira H; Ashwell MA; Carmel G; Xiang Y; Moir DT
    Antimicrob Agents Chemother; 2004 May; 48(5):1541-7. PubMed ID: 15105103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mechanism of drug action revealed by structural studies of enoyl reductase.
    Baldock C; Rafferty JB; Sedelnikova SE; Baker PJ; Stuitje AR; Slabas AR; Hawkes TR; Rice DW
    Science; 1996 Dec; 274(5295):2107-10. PubMed ID: 8953047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A triclosan-resistant bacterial enzyme.
    Heath RJ; Rock CO
    Nature; 2000 Jul; 406(6792):145-6. PubMed ID: 10910344
    [No Abstract]   [Full Text] [Related]  

  • 16. Exploring the interaction energies for the binding of hydroxydiphenyl ethers to enoyl-acyl carrier protein reductases.
    Muralidharan J; Suguna K; Surolia A; Surolia N
    J Biomol Struct Dyn; 2003 Feb; 20(4):589-94. PubMed ID: 12529157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of mixtures of quaternary ammonium compounds and hexachlorophene.
    WALTER GR; GUMP WS
    J Pharm Sci; 1962 Aug; 51():770-2. PubMed ID: 14004760
    [No Abstract]   [Full Text] [Related]  

  • 18. Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development.
    Mistry TL; Truong L; Ghosh AK; Johnson ME; Mehboob S
    ACS Infect Dis; 2017 Jan; 3(1):54-61. PubMed ID: 27756129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel and potent class of FabI-directed antibacterial agents.
    Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase.
    Perozzo R; Kuo M; Sidhu Ab; Valiyaveettil JT; Bittman R; Jacobs WR; Fidock DA; Sacchettini JC
    J Biol Chem; 2002 Apr; 277(15):13106-14. PubMed ID: 11792710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.